



05
2020

ZAMBIA ESSENTIAL MEDICINES LIST



ZAMBIA ESSENTIAL MEDICINES LIST

(ZEMPL)

Users of this publication are encouraged to send any comments and queries to the following address:

THE PERMANENT SECRETARY
MINISTRY OF HEALTH
NDEKE HOUSE
P.O Box 30205
LUSAKA-ZAMBIA
Email: ps@moh.gov.zm

Proposals for amendments to the list should be sent to the same address using the ZEML Amendment Form (Refer to Appendix)

CONTENTS

Acknowledgements	iv
Zambia National Formulary Committee 2017 - 2022	v
Introduction	1
Zambia Essential Medicines List	2
1. Medicines used in anaesthesia	2
2. Medicines acting on the gastrointestinal system	3
3. Medicines acting on the central nervous system	4
4. Medicines used in the treatment of infections	7
5. Medicines used in the treatment of endocrine system disorders, obstetrics, gynaecology, and contraception	15
6. Medicines used in the treatment of diseases of the respiratory system and allergy	19
7. Medicines used in the treatment of cardiovascular system disorders	20
8. Medicines used in the treatment of malignant disease: anti-neoplastic medicines	24
9. Medicines acting on the eye	26
10. Blood and Blood products	29
11. Nutrition	30

12. Medicines acting on the skin	31
13. Medicines used in the treatment of diseases of the ear, nose and throat	33
14. Medicines used in the treatment of musculoskeletal disorders	34
15. Immunological products	35
16. Antidotes and other substances used in poisoning	36
Appendices	37
Appendix 1: ZEML amendment form	38

Acknowledgements

The Zambia National Formulary Committee (ZNFC) is grateful to the Ministry of Health for the support given to the Committee during the preparation of this edition of the ZEML. The Committee would also like to thank the United Nations Population Fund (UNFPA) and Clinton Health Access Initiative (CHAI), respectively, for financial and technical support towards the preparation of the ZEML.

Technical advice and contributions were also received from various health professionals and institutions including; Zambia Medicines Regulatory Authority (ZAMRA), the Specialised and Teaching Hospitals, the Provincial Health Offices, and the cooperating partners. Throughout the process, various stakeholders were engaged to participate in review of documents, workshops, ZNF committee and secretariat meetings, validation session, and one-on-one meetings to solicit direct input and feedback.

The Committee would also like to thank Mr Emmanuel Mubanga, Mr Boyd Mwanashimbala, Mr Maxwell Kasonde, and Mrs Ilitongo Saasa-Sondashi from ZNFC Secretariat for co-writing and coordinating the team efforts that led to the finalization of the ZEML document.

We would like to acknowledge the European Union (EU) support for technical review of the ZEML document. A special thanks to CHAI for supporting the printing of this edition.



Dr Kennedy Malama
Permanent Secretary –Technical Services
MINISTRY OF HEALTH

ZAMBIA NATIONAL FORMULARY COMMITTEE 2017- 2022

- | | | |
|--|--|---|
| 1. Dr KOR CHIYEŊU
Consultant Physician, UTH (Chairperson) | 16. Mr Maxwell KASONDE
Public Health Pharmacist, MOH | 8. Ms Ellah ZINGANI
Lecturer, UNZA |
| 2. Mr Oliver HAZEMBA
Senior Technical Advisor, Management
Sciences for Health (Vice-Chairperson) | 17. Dr Gloria MUNTALI
Paediatric HIV Coordinator, MOH | 9. Dr Chileshe
Cardiologist, UTH |
| 3. Dr Owen NGALAMIKA
Dermatologist, UTH | 18. Dr Susan Citorje MUSADABWE
Senior Medical Superintendent, Cancer
Diseases Hospital | 10. Mr Peter LUKONDE
HIV Pharmacist, MOH |
| 4. Mr Pious HACHIZO
Senior Pharmacist, Cancer Diseases Hospital | 19. Dr. Francis SIMENDA
Consultant, Chainama Hills Hospital | 11. Mr Morton KUNGA
Chief TB Officer, MOH |
| 5. Mrs Ilitongo Saasa SONDASHI
Director, Logistics Medical Stores Limited | 20. Ms Anne ZULU
Director, Pharmaceutical Standards
Medical Stores Limited | 12. Mr Mathews MWALE
Chief Pharmacist, Copperbelt Province |
| 6. Mr Billy MWEETWA
Programme Officer, GHSC-PSM | 21. Mr Chikuta MBEWE
Managing Director, MSL | 13. Dr Justor BANDA
Renal Consultant, Clinical Care Specialist,
Copperbelt Province |
| 7. Dr Sally TROLLIP
Physician, UTH | | 14. Mr Keegan MWAPE
Chief Pharmacist, Copperbelt Province |
| 8. Dr Maureen CHISEMBELE
Obstetrician/Gynaecologist, UTH | Other Technical Reviewers: | 15. Mr Malama MALEMA
Chief Pharmacist, Muchinga Province |
| 9. Mr Enock CHIKATULA
Chief Pharmacist, Levy Mwanawasa University
Teaching Hospital | 1. Mr Chimuka HAMPANGO
Reproductive Health Commodity Security
Programme Analyst, UNFPA | 16. Chibosa KANDANDU
Chief Pharmacist, Central Province |
| 10. Dr Pauline Musukwa SAMBO
Oncologist, UTH | 2. Dr Angel MWICHE
Ass. Director Reproductive Health, MOH | 17. Mr Luke BIETE,
Clinical Pharmacist, MOH |
| 11. Mr Emmanuel Mubanga
Ass. Director, Pharmaceutical Services, MOH | 3. Mr Waza Bright MHANGO
Program Manager, CHAI | |
| 12. Mr Boyd MWANASHIMBALA
Chief Pharmacist, MOH | 4. Mr Emmanuel MUBANGA
Ass. Director Pharmaceutical Services, MOH | Secretariat: |
| 13. Mr Luke ALUTULI
Chief Pharmacist, UTH | 5. Dr Chichonyi A. KALUNGIA
Lecturer, UNZA | 1. Mr Maxwell KASONDE
Public Health Pharmacist, MOH |
| 14. Mr Abraham MUKESALA
Chief Pharmacist, Lusaka Province | 6. Mr Chiluba MWILA
Head, Department of Pharmacy, UNZA | 2. Mr Nyambe SITALI
Office Assistant, Cancer Diseases Hospital |
| 15. Dr Aggrey MWEEMBA Nephrologist, UTH | 7. Dr Jimmy HANGOMA
Lecturer & Clinical Pharmacist, Levy
Mwanawasa Medical University | 3. Mr Victor KAMUHUZA
Office Assistant |

INTRODUCTION

The criteria for the selection of essential medicines:

- The choice of essential medicines depends on factors which include: the pattern of prevalent diseases; the treatment facilities; the training and experience of available personnel; the financial resources; and the results of efficacy and safety evaluations obtained in controlled clinical trials and epidemiological studies and the performance in general use in a variety of healthcare settings.
- When several medicines are available for the same indication, only the medicine and the pharmacological form that provides the more convenient, benefit/risk ratio must be selected.
- When two or more medicines are therapeutically equivalent, the selection should be based on careful evaluation of their relative efficacy, safety, quality, price and availability. That is;
 - A medicine with which the health workers are familiar
 - A medicine with the most favourable pharmacokinetic properties
 - One that has been thoroughly investigated
 - In cost comparison, it must be medicine with the lowest cost of the total treatment, not only the unit cost of the medicine
 - And readily available medicine.

Most essential medicines must be formulated as single compounds. A fixed-dose combination should be accepted only if clinical documentation justifies the concomitant use of more than one medicine, and the combination provides a proven advantage over single compounds when administered separately in terms of therapeutic effect, safety, cost or patients adherence to treatment.

ZAMBIA ESSENTIAL MEDICINES LIST

	Medicine	Presentation	Level	VEN
1	Medicines used in anaesthesia			
1.1	General anaesthesia			
1.1.1	Intravenous and intramuscular anaesthetics			
1.1.1.1	Propofol	Emulsion for injection 10mg/ml	II - IV	V
1.1.1.2	Ketamine	Solution for injection 10mg/ml	II - IV	V
1.1.1.3	Etomidate	Powder for injection 1g and 500mg vials	II - IV	V
1.1.1.4	Thiopental sodium	Powder for injection 500mg vials	II - IV	V
1.1.2	Volatile inhalation anaesthetics			
1.1.2.1	Sevoflurane	Inhalation liquid 250ml	II - IV	V
1.1.2.2	Isoflurane	Inhalation liquid 250ml	II - IV	V
1.1.2.3	Halothane	Inhalation liquid 250ml	II - IV	V
1.1.3	Local anaesthetics			
1.1.3.1	Lignocaine	Solution for injection 2% w/v, 20mls	II - IV	E
1.1.3.2	Lignocaine with Adrenaline dental	Solution for injection	I - IV	E
1.1.3.3	Bupivacaine without preservatives	Solution for injection 50mg/ml, (2ml)	II - IV	E
1.1.3.4	Bupivacaine	Solution for injection 0.5% w/v	II - IV	E
1.1.3.5	Bupivacaine with glucose	Solution for injection 0.5% + 8% w/v	I - IV	E
1.1.4	Anticholinesterases			
1.1.4.1	Neostigmine	Solution for injection 2.5mg/ml, (1ml)	II - IV	V

	Medicine	Presentation	Level	VEN
2	Medicines acting on Gastrointestinal System			
2.1	Antacids			
2.1.1	Aluminium hydroxide + Magnesium trisilicate	Gel, Chewable tablets	I - IV	E
2.1.2	Aluminium hydroxide	Gel 4%; Tablets 500mg, Oral suspension 4%	I - IV	E
2.1.3	Magnesium trisilicate	Chewable tablets 250mg	I - IV	E
2.1.4	Sodium citrate	Chewable tablets	I - IV	E
2.2	Antispasmodics			
2.2.1	Hyoscine butyl bromide	Solution for injection 20mg/ml (1ml), Tablets 10mg	II - IV	E
2.3	Anti-ulcer medicines			
2.3.1	Cimetidine	Tablets 200mg, 400mg, 800mg; Syrup/suspension 200mg/5ml, Solution for injection 100mg/ml	II - IV	E
2.3.2	Ranitidine	Tablets 150mg, 300mg, Solution for injection 25mg/ml	II - IV	E
2.3.3	Famotidine	Tablets 20mg, 40mg	II - IV	E
2.3.4	Omeprazole	Tablets 10mg, 20mg	II - IV	E
2.3.5	Esomeprazole	Tablet/capsule 20mg/40mg, Solution for injection 20mg	I - IV	E
2.4	Antidiarrhoeals			
2.4.1	Codeine phosphate	Tablets 15mg, 30mg, 60mg	II - IV	E
2.4.2	Loperamide	Tablets/Capsules 2mg, Syrup 1mg/ml	II - IV	E

	Medicine	Presentation	Level	VEN
2.5	Laxatives			
2.5.1	Lactulose	Suspension	III	E
2.5.2	Glycerol	Suppository 1g, 4g	I - IV	E
2.5.3	Senna	Tablets 7.5mg, Suppositories	I - III	E
2.5.4	Bisacodyl	Tablets 5mg	I - IV	E
2.6	Medicines used for treating haemorrhoids			
2.6.1	Bismuth subgallate + Zinc oxide + Lidocaine hydrochloride	Suppository, Cream	II - IV	E
3	Medicines acting on the Central Nervous System			
3.1	Anxiolytics and Antipsychotics			
3.1.1	Clonazepam	Tablet 0.5mg	III - IV	E
3.1.2	Lorazepam	Tablets 2mg	III - IV	E
3.1.3	Midazolam	Solution for injection 5mg, 15mg	III - IV	E
3.1.4	Diazepam	Tablets 2mg, Solution for injection 5mg/ml (2ml)	I - III	V
3.2	Selective serotonin reuptake inhibitors			
3.2.1	Fluoxetine	Tablets 20mg, 50mg	II - III	E
3.2.2	Sertraline	Tablet 60mg	IV	E
3.2.3	Duloxetine	Tablet 5mg	IV	E
3.2.4	Citalopram	Tablet 10mg, 20mg	IV	E

	Medicine	Presentation	Level	VEN
3.3	Tricyclic Antidepressants			
3.2.1	Amitriptyline	Tablets 25mg	III	E
3.2.2	Imipramine	Tablets 25mg	III	E
3.2.3	Clomipramine	Tablets 25mg	III	E
3.3	Mood stabilizers			
3.3.1	Lithium carbonate	Tablets 300mg	IV	E
3.3.2	Sodium valproate	Tablets 200mg	II - IV	E
3.3.3	Divalproex sodium	Tablet 500mg	IV	E
3.4	Antiepileptic medicines			
3.4.1	Carbamazepine	Tablets 200mg, injection 5mg/ml	II - IV	V
3.4.2	Lamotrigine	Tablets 25mg, 50mg	I - IV	V
3.4.3	Ethosuximide	Capsules 250mg	III - IV	V
3.4.4	Phenobarbitone	Tablets 30mg, Solution for injection 200mg/ml	II - IV	V
3.4.5	Phenytoin	Tablets 100mg, Solution for injection 250mg	II - IV	V
3.4.6	Sodium valproate	Tablets 200mg, Syrup 200mg/5ml	II - IV	V
3.4.9	Gabapentin	Tablets 600mg, Oral solution 250mg/5ml	IV	E
3.4.10	Levetiracetam	Tablets 200mg	IV	E

	Medicine	Presentation	Level	VEN
3.5	Medicines used in Parkinsonism and related disorders			
3.5.1	Bezhexol	Tablets 5mg	II - IV	V
3.5.2	Bromocriptine	Tablets 2.5mg	III - IV	E
3.5.3	Procyclidine	Tablets 5mg, injection 5mg/ml,(2ml)	I - IV	E
3.6	Medicines used for Nausea and Vomiting			
3.6.1	Cyclizine	Tablets 50mg, Solution for injection 50mg/ml	IV	E
3.6.2	Domperidone	Tablets 10mg	II - IV	E
3.6.3	Metoclopramide	Tablets 10mg, Solution for injection 5mg/ml (2ml)	II - IV	E
3.6.4	Prochlorperazine	Tablets 5mg	III - IV	E
3.6.5	Promethazine	Tablet 25mg, Solution for injection 25mg/ml (2ml)	I - IV	V
3.6.6	Ondansetron	Tablets 4mg, Oral suspension 2mg, Solution for injection 8mg/2ml	II - IV	E
3.7	Analgesics			
3.7.1	Non-opioids analgesics			
3.7.1.1	Paracetamol (Acetaminophen)	Tablets 100mg, 500mg, Suppository 125mg, 250mg, Syrup 120mg/5ml	I - IV	V
3.8	Non-Steroidal anti-Inflammatory Medicines			
3.8.1	Aspirin	Tablets 75mg, 300mg	II - IV	E
3.8.2	Ibuprofen	Tablets 200mg, 400mg	II - IV	E

	Medicine	Presentation	Level	VEN
3.8.3	Diclofenac	Tablets 50mg, 100mg, Solution for injection 75mg	II - IV	E
3.8.4	Mefenamic acid	Tablets 250mg, 500mg, Suppository 125mg	II - IV	E
3.9	Opioid analgesics			
3.9.1	Morphine	Powder, Oral syrup 10mg/5ml, Solution for injection 10mg/ml ampoule	II - IV	V
3.9.2	Pethidine	Tablets 50mg, Solution for injection 50mg/ml	II - IV	V
3.9.3	Tramadol	Tablets 50mg, Solution for injection 50mg/ml	II - IV	E
3.9.4	Fentanyl	Solution for injection 50mcg/ml	II - IV	E
3.10	Anti-migraine medicines			
3.10.1	Ergotamine tartrate	Tablets 1mg	II - IV	E
4	Medicines used in the treatment of infections			
4.1	Antibacterial medicines			
4.1.1	Penicillins			
4.1.1.1	Benzathine penicillin	Powder for injection 2.4 MU vial	I - IV	E
4.1.1.2	Benzylpenicillin	Powder for injection 5 MU vial	I - IV	V
4.1.1.3	Phenoxyethylpenicillin	Tablets 250mg, Oral suspension 125mg/5ml	I - IV	E

	Medicine	Presentation	Level	VEN
4.1.2	Broad-spectrum penicillins			
4.1.2.1	Amoxycillin	Tablets/Capsules 250mg, Syrup 125mg/5ml	I - IV	V
4.1.2.2	Ampicillin	Powder for injection 500mg vial	III - IV	V
4.1.3	Penicillinase-resistant penicillins			
4.1.3.1	Amoxicillin + Clavulanic acid (Co-amoxiclav)	Tablets 375mg (250mg + 125mg), 625mg (500mg + 125mg)	III - IV	E
4.1.3.2	Cloxacillin	Capsules 250mg, Powder for injection 500mg	II - IV	V
4.1.3.3	Flucloxacillin	Capsules 250mg, Powder for injection 250mg	III - IV	E
4.1.4	Aminoglycosides			
4.1.4.1	Gentamicin	Solution for injection 40mg/ml, (2ml)	I - IV	V
4.1.5	Sulphonamides			
4.1.5.1	Sulfamethoxazole + Trimethoprim (Co-trimoxazole)	Tablets 120mg, 480mg, Oral suspension 240mg/5ml, Solution for injection 480mg	I - IV	V

	Medicine	Presentation	Level	VEN
4.1.6	Quinolones			
4.1.6.1	Ciprofloxacin	Tablets 250mg, 500mg Solution for injection 2mg/ml 100ml, 100ml bottle	III - IV IV	E
4.1.6.2	Nalidixic acid	Tablets 500mg, Oral suspension 30mg/5ml	I - IV	V
4.1.6.3	Ofloxacin	Tablets 400mg, Solution of injection 2mg/ml	I - V	E
4.1.7	Nitro-furan medicines			
4.1.7.1	Nitrofurantoin	Tablets 100mg	I - IV	E
4.1.8	Macrolides			
4.1.8.1	Erythromycin	Tablets 250mg, Powder for injection 500mg vial, Oral suspension 125mg/5ml	I - IV	V
4.1.8.2	Azithromycin	Capsules/Tablets 250mg, Oral suspension 200mg/5ml	II - IV	V
4.1.8.3	Clarithromycin	Tablet 250mg, 500mg	II - IV	V
4.1.9	Lincosamides			
4.1.8.3	Clindamycin	Capsules 75mg, Oral suspension 75mg/5ml, Solution for injection 150mg/ml	III - IV	E
4.1.10	Cephalosporins and Cephamycins			
4.1.9.1	Cefotaxime	Powder for injection 1g, 250mg vial	III - IV	E
4.1.9.2	Cefoxitine	Powder for injection 1g, 2g vial	II - IV	E

	Medicine	Presentation	Level	VEN
4.1.9.3	Ceftriaxone	Powder for injection 250mg, 1g vial	II - IV	E
4.1.9.4	Cephalexin	Tablets/ Capsules 250mg, Oral suspension 125mg/5ml	III - IV	E
4.1.9.5	Cefuroxime	Tablets 250mg, 500mg, Oral suspension 125mg/5ml	III - IV	E
4.1.9.6	Cefipime	Powder for injection 1g, 2g vial	III - IV	E
4.1.10	Tetracyclines			
4.1.10.1	Doxycycline	Tablets/Capsule 100mg	I - IV	E
4.1.10.2	Tetracycline	Capsule 250mg, Eye ointment 3%	I - IV	E
4.1.11	Nitroimidazoles			
4.1.11.1	Metronidazole	Tablets 200mg, Solution for infusion 5mg/ml 100mls, Oral suspension 100mg/5ml, 100ml	I - IV	V
4.1.11.2	Tinidazole	Tablets 500mg	I - IV	E
4.1.12	Other antibacterials			
4.1.12.1	Chloramphenicol	Capsules 250mg, Oral suspension 125mg/5ml, Powder for injection 1g vial	III - IV	V

	Medicine	Presentation	Level	VEN
4.2	Anti-tuberculosis medicines			
4.2.1	Rifampicin + Isoniazid	Tablets 150mg + 75mg	HC, I - IV	V
4.2.2	Rifampicin + Isoniazid	Tablets 75mg + 50mg	I - IV	V
4.2.3	Rifampicin + Isoniazid + Ethambutol	Tablets 150mg + 75mg + 275mg	I - IV	V
4.2.4	Rifampicin + Isoniazid + Pyrazinamide	Tablets 75mg + 50mg + 150mg	I - IV	V
4.2.5	Rifampicin + Isoniazid + Ethambutol + Pyrazinamide	Tablets 150mg + 75mg + 275mg+ 400mg	I - IV	V
4.2.6	Ethambutol	Tablets 400mg	I - IV	V
4.2.7	Pyrazinamide	Tablets 400mg	I - IV	V
4.2.8	Isoniazid	Tablets 100mg,150mg	I - IV	V
4.2.9	Streptomycin	Solution for injection 1g, 5g vial	I - IV	V
4.2.10	Capreomycin	Powder for injection 1g	I - IV	V
4.2.11	Levofloxacin	Tablets 250mg	I - IV	V
4.2.12	Ethionamide	Tablets 250mg	II - IV	V
4.2.13	Cycloserine	Tablets 250mg	II - IV	V
4.2.14	Bedaquiline	Tablet 100mg	II - IV	V
4.2.15	Delamanide	Tablet 50mg	II - IV	V
4.2.16	Linezolid	Tablet 600mg	II - IV	V
4.2.17	Clofazimine	Tablet 100mg	II - IV	V
4.2.18	Moxifloxacin	Tablet 400mg	II - IV	V

	Medicine	Presentation	Level	VEN
4.3	Anti-leprosy medicines			
4.3.1	Clofazimine	Capsules 50mg,100mg	HC I - IV	V
4.3.2	Dapsone	Tablets 10mg,25mg,50mg	HC I - IV	V
4.3.3	Rifampicin	Capsules 150mg, 300mg, Oral syrup 100mg/5ml	HC I - IV	V
4.4	Antifungal medicines (<i>also see section 12.3 and 13.3</i>)			
4.4.1	Amphotericin B	Solution for injection 50mg	III - IV	E
4.4.2	Clotrimazole	Topical cream 1%, Vaginal tablet 500mg, Mouth paint	HC, I - IV	E
4.4.3	Fluconazole	Capsule 50mg, 150mg, 200mg, Solution for injection 2mg/ml	I - IV	V
4.4.4	Flucytosine	Tablet 250mg, Solution for injection 10mg/ml	III - IV	E
4.4.5	Griseofulvin	Tablets 125mg, 250mg, 500mg, Oral suspension 125mg/5ml	HC, I - IV	E
4.4.6	Miconazole	Topical cream 2%	I - IV	E
4.4.5	Terbinafine	Tablet 250mg, Topical cream/ointment 1%	II - IV	E
4.4.6	Itraconazole	Tablets 100mg	III - IV	E
4.4.6	Nystatin	Vaginal tablets 100,000 IU, Oral suspension 100,000 IU, Tablets/Capsules 100,000 IU	HC, I - IV	V
4.5	Anti-protozoal medicines			
4.5.1	Antimalarials			
4.5.1.1	Artemether + Lumefantrine	Tablets 20mg/120mg	I - IV	V
4.5.1.2	Pyrimethamine + Sulphadoxine	Tablets 25mg/500mg	I - IV	V

	Medicine	Presentation	Level	VEN
4.5.1.3	Quinine	Tablets 300mg, Solution for injection 300mg/1ml (2ml)	I - IV	V
4.5.1.4	Artesunate	Powder for injection 60mg, 120mg, Suppository 100mg, 200mg Tablet 50mg	HC, I - IV	V
4.5.2	Amoebocides (See section 4.1.11)			
4.6	Trypanomicides			
4.6.1	Melarsoprol	Solution for injection 3.6%	III - IV	V
4.6.2	Suramin sodium	Powder for injection 1g vial	III - IV	V
4.6.1	Pentamidine isethionate	Powder for nebulizer solution 300mg	II - IV	V
4.8	Antivirals			
4.8.1	Acyclovir	Tablets 200mg, 400mg, Topical cream 5%, Solution for injection 50mg/ml, Powder for injection 500mg, 1g vial, Ophthalmic ointment 3%	II - IV	E
4.9	Antiretroviral Medicines used in HIV infection			
4.9.1	Abacavir	Tablets 300mg	II - IV	E
4.9.2	Lamivudine	Tablets 150mg	II - IV	E
4.9.3	Zidovudine + Lamivudine	Tablets 60mg + 30mg	II - IV	E
4.9.4	Abacavir + Lamivudine	Tablets 60mg + 30mg, 120mg + 60mg	II - IV	E

	Medicine	Presentation	Level	VEN
4.9.5	Lopinavir/Ritonavir	Oral suspension 80mg/20mg, 100mg/25mg	II - IV	E
4.9.6	Raltegravir	Tablets 100mg	II - IV	E
4.9.7	Tenofovir/Lamivudine	Tablets 300mg/300mg	II - IV	E
4.9.8	Zidovudine	Tablets 100mg, 250mg	II - IV	E
4.9.9	Tenofovir/Lamivudine/Efavirenz	Tablets 300mg/300mg/400mg	II - IV	E
4.9.10	Tenofovir/Lamivudine/Dolutegravir	Tablets 300mg /300mg/50mg	II - IV	E
4.9.11	Tenofovir alafenamide/Emitricitabine/Dolutegravir	Tablets 25mg/200/50mg	II - IV	E
4.9.12	Emitricitabine	Tablets 200mg	II - IV	E
4.9.13	Tenofovir/Emitricitabine	Tablets 300/200mg	II - IV	E
4.9.14	Efavirenz	Tablets 200mg, 400mg	II - IV	E
4.9.15	Nevirapine	Tablets 200mg, Oral suspension 10mg/ml	II - IV	E
4.9.16	Etravirine	Tablets 100mg	II - IV	E
4.9.17	Ritonavir	Tablets 100mg	II - IV	E
4.9.18	Lopinavir/Ritonavir	Tablets 80/20mg, 200/50mg	II - IV	E
4.10	Antihelminthics			
4.10.1	Mebendazole	Chewable tablets 100mg, 500mg	HC, HP, I - IV	E
4.10.2	Niclosamide	Tablets 500mg	I - IV	E
4.10.3	Pyrantel pamoate	Tablets 125mg, Oral suspension 250mg/5ml	I - IV	E
4.10.4	Thiabendazole	Tablets 500mg	II - IV	E
4.10.5	Albendazole	Tablets 400mg	II - IV	E

	Medicine	Presentation	Level	VEN
4.11	Schistosomicides			
4.11.1	Praziquantel	Tablets 600mg	I - IV	V
4.12	Anti-filarials			
4.12.1	Diethylcarbamazine	Tablets 50mg	III - IV	E
4.12.2	Ivermectin	Tablets 3mg	III - IV	E
5	Medicines used for endocrine system disorders, obstetrics, gynaecology and contraception			
5.1	Medicines used in Diabetes mellitus			
5.1.1	Insulins			
5.1.1.1	Short acting (soluble) Insulin	Solution for injection 100 IU/ml 10ml vial	II - IV	V
5.1.1.2	Isophane Insulin, Biphasic Insulin	Solution for injection 100IU/ml 10ml	II - IV	V
5.1.1.3	Actraphane or Mixtard (30/70) Intermediate and long-acting Insulin	Solution for injection 100IU/ml 10ml, Pre-filled penset 300IU/3mls	II - IV	V
5.1.2	Oral hypoglycaemics			
5.1.2.1	Glibenclamide	Tablets 5mg	II - IV	V
5.1.2.3	Metformin	Tablets 500mg	II - IV	V
5.1.2.4	Gliclazide	Tablet 30mg	HC, I - IV	E
5.1.2.5	Glimepiride	Tablets 1mg, 2mg	HC, I - IV	E
5.1.3	Medicines for hypoglycaemia			
5.1.3.1	Glucagon	Powder & Solvent for injection 1mg	II - IV	V

	Medicine	Presentation	Level	VEN
5.2	Medicines acting on the thyroid			
5.2.1	Carbimazole	Tablets 5mg	III - IV	E
5.2.2	Iodine aqueous	Oral solution	III - IV	E
5.2.3	Thyroxine	Tablets 50mcg, 100mcg	III - IV	V
5.3	Corticosteroids			
5.3.1	Dexamethasone	Tablets 500mcg, Solution for injection 5mg/ml (5ml)	III - IV	V
5.3.2	Hydrocortisone sodium succinate	Powder for injection 100mg vial	I - IV	V
5.3.3	Prednisolone	Tablets 5mg	I - IV	V
5.4	Oestrogens and progestogens			
5.4.1	Norethisterone	Tablets 5mg	III - IV	E
5.4.2	Conjugated Oestrogens	Tablets 625mcg	III - IV	E
5.5	Androgens and anti-androgens			
5.5.1	Cyproterone	Tablets 50mg	III - IV	E
5.5.2	Stilboestrol	Tablets 1mg	III - IV	E
5.5.3	Testosterone undecanoate	Capsules 40mg, Solution for injection (oily depot) 250mg/ml,(1ml)	III - IV	E

	Medicine	Presentation	Level	VEN
5.6	Other endocrine medicines			
5.6.1	Bromocriptine	Tablets 2.5mg	III - IV	E
5.6.2	Clomiphene citrate	Tablets 50mg	III - IV	E
5.6.3	Danazol	Capsules 100mg	III - IV	E
5.7	Medicines used in obstetrics and gynaecology			
5.7.1	Medicines acting on smooth muscle			
5.7.1.1	Anticonvulsants			
5.7.1.1.1	Magnesium sulphate	Solution for injection 50%	II - IV	E
5.7.1.2	Prostaglandin Analogues and Oxytocics			
5.7.1.2.1	Dinoprostone	Tablets 500mcg, Solution for injection 1mg/ml	III - IV	E
5.7.1.2.2	Ergometrine maleate	Tablets 250mcg, 500mcg, Solution for injection 200mcg/ml	II - IV	V
5.7.1.2.3	Ergometrine + Oxytocin	Solution for injection 50mcg/5 IU	II - IV	E
5.7.1.2.4	Oxytocin	Solution for injection 10 IU/ml, 1ml	II - IV	V
5.7.1.2.5	Carbetocin (heat stable)	Solution for injection 100mcg/ ml	HC, I - IV	V
5.7.1.2.6	Misoprostol	Tablets 200mcg	I - IV	V
5.7.1.2.7	Mifepristone	Tablets 200mg	II - IV	V
5.7.1.2.8	Mifepristone + Misoprostol	Tablets 200mg/200mcg	II - IV	V

	Medicine	Presentation	Level	VEN
5.7.1.3	Myometrial relaxants			
5.7.1.3.1	Salbutamol	Solution for injection 500mcg/ml (1ml)	II - IV	V
5.7.1.3.2	Nifedipine	Immediate release capsule, 10mg	HC, I - IV	V
5.7.1.4	Other medicines administered to the pregnant woman			
5.7.1.5.1	Dexamethasone phosphate	Solution for injection 4mg/ ml	HC, I - III	V
5.7.1.5.2	Tranexamic acid	Tablets 500mg, Solution for injection 100mg/ ml	HC, I - III	V
5.8	Contraceptives			
5.8.1	Combined oral contraceptives			
5.8.1.1	Ethinylestradiol/levonorgestrel	Tablets 30mg/150mcg	I - IV	V
5.8.2	Emergency contraception			
5.8.2.1	Levonorgestrel	Tablets 750mcg, 1.5mg	I - IV	V
5.8.3	Progesterone-only oral contraceptives			
5.8.3.1	Levonorgestrel	Tablets 30mcg	I - IV	V
5.8.4	Progesterone-only injectable contraceptives			
5.8.4.1	Medroxyprogesterone acetate	Suspension for injection 150mg/ml, 1ml Pre-filled subcutaneous injection 104mg/ 0.65ml	I - IV	V
5.8.4.2	Norethisterone enanthate	Solution/Emulsion for injection 200mg/ml, 1ml	I - IV	V
5.8.5	Barrier methods			
5.8.5.1	Female condoms	Artificial plastic sheath	HC, I - IV	V
5.8.5.2	Male condoms	Latex sheath with/without spermicide	HC, I - IV	V

	Medicine	Presentation	Level	VEN
5.8.5.3	Copper coil intrauterine device	Copper long coil type (Copper T 380A) Intrauterine device (IUD)	I - IV	V
5.8.5.4	Levonorgestrel-releasing intrauterine system	Intrauterine device LNG-IUS 52mg	I - IV	V
5.8.5.5	Menfegol spermicidal vaginal foaming	Forming tablets	I - IV	E
5.8.6	Implants			
5.8.6.1	Levonorgestrel implant	Two rods, 75 mg each	IV	V
5.8.6.2	Etonogestrel implant	Single rod- releasing implant 68 mg	IV	V
6	Medicines used in the treatment of respiratory system disorders and allergy			
6.1	Anti-asthmatic medicines and medicines for chronic obstructive pulmonary disorder			
6.1.1	Adrenaline	Solution for injection 1 in 1000, (1ml)	I - IV	V
6.1.3	Salbutamol	Tablets 2mg, Oral syrup 2mg/5ml	I - IV	V
		Inhaler 100mcg/dose, Nebuliser liquid 2mg/ml	I - IV	E
6.2	Corticosteroids			
6.2.1	Hydrocortisone sodium succinate	Powder for injection 100mg vial	I - IV	V
6.2.2	Prednisolone	Tablets 5mg	II - IV	V

	Medicine	Presentation	Level	VEN
6.3	Asthma prophylaxis therapy			
6.3.1	Beclomethasone	Inhaler 50mcg/dose	II - IV	E
6.3.2	Sodium cromoglicate	Inhaler 5mg/dose	II - IV	E
6.3.3	Ipratropium bromide	Inhaler 20mcg/ metered dose	II - IV	E
	Budesonide + Formoterol	Inhaler 100mcg + 6mcg or 200mcg + 6mcg	II - IV	E
6.4	Antihistamines			
6.4.1	Chlorpheniramine	Syrup, Tablets 4mg	I - IV	E
6.4.2	Promethazine	Syrup, Tablets 10mg, Solution for injection 5mg/ml	I - IV	E
6.4.3	Loratidine	Oral liquid 1mg/ml, Tablets 10mg	HC, I - IV	E
6.5	Oxygen therapy			
6.5.1	Oxygen	Medical gas	I - IV	V
7	Medicines used in the treatment of cardiovascular system disorders			
7.1	Cardiac glycosides			
7.1.1	Digoxin	Tablets 250mcg, Solution for injection 250mcg/ml, (2ml), Elixir 50mcg/ml	II - IV	V
7.2	Diuretics			
7.2.1	Thiazides			
7.2.1.2	Bendrofluazide	Tablets 5mg	II - IV	E

	Medicine	Presentation	Level	VEN
7.2.1.3	Hydrochlorthiazide	Tablets 50mg	II - IV	E
7.2.2	Loop diuretics			
7.2.2.1	Furosemide	Tablets 40mg, Solution for injection 10mg/ml, (2ml)	II - IV	V
7.2.3	Potassium-sparing diuretics			
7.2.3.1	Amiloride + Hydrochlorthiazide	Tablets 5mg/50mg	II - IV	E
7.2.4	Osmotic diuretics			
7.2.4.1	Mannitol	Solution for injection 20% (250ml bottle)	II - IV	V
7.3	Antiarrhythmic medicines			
7.3.1	Amiodarone	Tablets 100mg, Solution for injection	III - IV	E
7.3.2	Atenolol	Tablets 50mg	II - IV	E
7.3.3	Digoxin	Tablets 250mcg, Solution for injection 250mcg/ml (2ml)	II - IV	V
7.3.4	Lignocaine	Solution for injection 1%, (10ml, 25ml)	II - IV	V
7.3.5	Quinidine	Tablets 200mg, 300mg	IV	V

	Medicine	Presentation	Level	VEN
7.4	Anti-angina medicines			
7.4.1	Atenolol	Tablets 50mg	III - IV	E
7.4.2	Glyceryl trinitrate	Sub-lingual tablets 500mcg	II - IV	E
7.4.3	Isosorbide mononitrate	Tablets 10mg	II - IV	E
7.4.4	Nifedipine	Tablets or Capsules 10mg	II - IV	E
7.5	Antihypertensive medicines			
7.5.1	Thiazide diuretics			
7.5.1.1	Hydrochlorthiazide	Tablets 50mg	II - IV	E
7.5.1.2	Potassium-sparing diuretics			
7.5.1.2.1	Amiloride + Hydrochlorthiazide	Tablets 5mg/50mg	II - IV	E
7.5.1.2.2	Spironolactone	Tablets 25mg	II - IV	E
7.5.2	Beta- adrenoceptor blockers			
7.5.2.1	Atenolol	Tablets 50mg	II - IV	E
7.5.2.2	Propranolol	Tablets 10mg, 40mg	II - IV	E
7.5.2.3	Carvedilol	Tablets 3.125mg	IV	E
7.5.2.4	Labetalol	Tablets 100mg, Solution for injection 5mg/ml	III - IV	E
7.5.2.5	Metoprolol	Tablets 50mg, 100mg	III - IV	E

	Medicine	Presentation	Level	VEN
7.5.3	Vasodilators			
7.5.3.1	Hydralazine	Tablets 25mg, Solution for injection 20mg ampoule	II - IV	E
7.5.4	Angiotensin converting enzyme (ACE) inhibitors			
7.5.4.1	Captopril	Tablets 25mg	III - IV	E
7.5.4.2	Lisinopril	Tablets 5mg, 10mg, 25mg	III - IV	E
7.5.4.3	Enalapril	Tablets 5mg, 10mg, 20mg	III - IV	E
7.5.5	Angiotensin II receptor blockers			
7.5.5.1	Losartan	Tablets 25mg, 50mg	IV	E
7.5.5.2	Losartan + Hydrochlorthiazide	Tablets 50mg/12.5mg	HC, I - IV	E
7.5.5.3	Telmisartan + Hydrochlorthiazide	Tablets 40mg/12.5mg	HC, I - IV	E
7.5.6	Calcium channel blockers			
7.5.6.1	Nifedipine	Tablets or Capsules 10mg, 20mg	III - IV	E
7.5.6.2	Verapamil	Tablets 40mg	III - IV	E
7.5.6.3	Amlodipine	Tablets 5mg, 10mg	III - IV	E
7.5.7	Centrally acting antihypertensives			
7.5.7.1	Methyldopa	Tablets 250mg	HC, I - IV	E

	Medicine	Presentation	Level	VEN
7.6	Medicines used in shock - sympathomimetics			
7.6.1	Adrenaline	Solution for injection 1 in 1000 (1mg/ml)	I - IV	V
7.7	Alpha-adrenoceptor blocking agents			
7.7.1	Prazosin	Tablets 500mcg, 1mg	III - IV	E
7.8	Lipid-regulating medicines			
7.8.1	Statins			
7.8.1.1	Simvastatin	Tablets 20mg, 40mg	IV	E
7.8.1.2	Atorvastatin	Tablets 20mg, 40mg	II - IV	E
7.9.1	Inotropic medicines			
7.9.1.1	Dopamine	Solution for injection 40mg/ml	IV	E
8	Medicines used in the treatment of malignant diseases:			
	Anti-neoplastic medicines			
8.1	Actinomycin D (Dactinomycin)	Powder for injection 500mcg	III - IV	V
8.2	Asparaginase	Powder for injection 1000 IU	III - IV	V
8.3	Azathioprine	Tablets 50mg, injection 50mg vial	IV	V
8.4	Bleomycin	Powder for injection 15 000 unit ampoule	IV	V
8.5	Busulphan	Tablets 500mcg	IV	V
8.6	Calcium folinate	Tablets 15mg	IV	V
8.7	Carboplatin	Solution for injection 10mg/ml	IV	V
8.8	Carmustine	Powder for injection 100mg vial	IV	V

	Medicine	Presentation	Level	VEN
8.9	Chlorambucil	Tablets 2mg	IV	V
8.10	Cisplatin	Solution for injection 1mg/ml	IV	V
8.11	Cyclophosphamide	Tablets 50mg, Powder for injection 100mg	IV	V
8.12	Cytarabine (Cytosine arabinoside)	Powder for injection 100mg, 500mg, 1g vial	IV	V
8.13	Cyproteron acetate	Tablets 50mg, 100mg	IV	V
8.14	Dacarbazine	Powder for injection 200mg vial	IV	V
8.15	Daunorubicin	Powder for injection 20mg vial	IV	V
8.16	Doxorubicin	Powder for injection 10mg,50mg	IV	V
8.17	Etoposide	Solution for IV infusion 20mg/ml	IV	V
8.18	Fludarabine	Tablets 10mg, Solution for injection, infusion 40mg/m ²	IV	V
8.19	Filgrastim	Solution for injection 300mcg/ml	IV	V
8.20	Fluorouracil	Solution for injection 25mg/ml	IV	V
8.21	Hydroxyurea	Capsules 500mg	IV	V
8.22	Ifosfamide	Powder for injection 1g, 2g vial	IV	V
8.23	Imatinib	Tablets 100mg	IV	V
8.24	Interferon	Solution for injection 300mg	IV	V
8.25	Lomustine	Capsules 40mg	IV	V
8.26	Melphalan	Tablets 2mg, Solution for injection 100mg	IV	V
8.27	Mercaptopurine	Tablets 50mg	IV	V
8.28	Methotrexate	Tablets 2.5mg, Solution for injection 50mg	IV	V
8.29	Mitomycin	Solution for injection 40mg	IV	V
8.30	Mustine	Solution for injection 10mg	IV	V
8.31	Paclitaxel	Solution for IV infusion 6mg/ml	IV	V
8.32	Procarbazine	Capsules 50mg	IV	V
8.33	Stilboestrol (Diethylstilbestrol)	Tablets 1mg	IV	V
8.34	Tamoxifen	Tablets 20mg	IV	V

	Medicine	Presentation	Level	VEN
8.37	Thioguanine	Tablets 40mg	IV	V
8.38	Vinblastine	Solution for injection 1mg/ml	IV	V
8.39	Vincristine	Solution for injection 1mg, 5mg	III - IV	V
9	Medicines acting on the eye			
9.1	Ophthalmic diagnosis			
9.1.1	Fluorescein sodium	Eye drops, strips	III - IV	E
9.2	Anti-infective preparations			
9.2.1	Antibacterial			
9.2.1.1	Chloramphenicol	Eye drops 0.5%, Eye ointment 1%	II - IV	E
9.2.1.2	Chloramphenicol + Dexamethasone	Eye drops 15%/ 0.1%	III - IV	E
9.2.1.3	Tetracycline	Eye ointment 1%	I - IV	E
9.2.1.4	Oxy-tetracycline + Hydrocortisone	Eye drops 3%/ 1%	III - IV	E
9.2.1.5	Neomycin + Betamethasone	Eye drops 0.5%/ 0.1%	III - IV	E
9.2.1.6	Gentamicin	Eye drops 0.3%	II - IV	E
9.2.1.8	Ofloxacin	Solution 0.3%	III - IV	E

	Medicine	Presentation	Level	VEN
9.2.2	Antifungals <i>(Preparations are not generally available and could be prepared extemporaneously)</i>			
9.2.2.1	Povidine Iodine	Eye drops 0.5%	III - IV	E
9.2.2.2	Natamycin	Eye suspension 5%	IV	E
9.2.3	Antiviral			
9.2.3.1	Aciclovir	Eye ointment	III – IV	E
9.3	Anti-inflammatory preparations			
9.3.1	Hydrocortisone acetate	Eye drops, eye ointment	II - IV	E
9.3.2	Dexamethasone	Eye drops 0.1%	III – IV	E
9.3.4	Tropicamide	Eye drops 1%	III – IV	E
9.3.5	Sodium cromoglycate	Eye drops 2%	III - IV	E
9.4	Miotics and anti-glaucoma medicines			
9.4.1	Pilocarpine	Eye drops 2%, 4%	III – IV	E
9.5	Mydriatic medicines			
9.5.1	Atropine sulphate	Eye drops 1%	III - IV	E

	Medicine	Presentation	Level	VEN
9.6	Systemic preparations			
9.6.1	Acetazolamide sodium	Tablets 250mg	III - IV	V
9.7	Local anaesthetics			
9.7.1	Lignocaine hydrochloride	Eye drops 4%	III - IV	E
9.8	Prostaglandin Analogue			
9.8.1	Latanoprost	Eye drops 50mcg/ml	IV	E
9.9	Sympathomimetics			
9.9.1	Dipivefrine	Eye drops 0.1%	IV	E
9.10	Beta-adrenoceptor blocker			
9.10.1	Timolol maleate	Eye drops 0.25%, 0.5%	III - IV	E
9.11	Diuretics			
9.11.1	Cyclopentiazide	Tablets 0.5mg	IV	E
9.12	Artificial tears			
9.12.1	Hypromellose	Eye drops 0.3mg	III - IV	E

	Medicine	Presentation	Level	VEN
9.13	Hyperosmotic agents			
9.13.1	Mannitol	Solution in water 20%	III - IV	E
9.13.2	Urea	Solution 30% in 10% invert sugar	III - IV	E
10	Blood and Blood Products			
10.1	Anti-coagulants			
10.1.1	Heparin (Unfractionated)	Solution for injection 5000IU/ml, 1ml	II - IV	V
10.1.2	Enoxaparin	Solution for injection 100mg/ml, Pre-filled syringes	II - IV	V
10.1.3	Warfarin	Tablets 1mg, 5mg	II - IV	V
10.2	Anti-haemorrhagic medicines			
10.2.1	Aminocaproic acid	Effervescent powder 3g, Oral suspension 10mg/5ml	III - IV	E
10.2.2	Tranexamic acid	Solution for injection 100mg/ml, Tablets 650mg	III - IV	E
10.2.2	Fibrinogen	Dry or freeze dried powder for injection	III - IV	V
10.2.3	Human anti-haemophiliac fraction (dried)	Solution for reconstitution 3 units/ml	IV	E
10.2.4	Phytomenadione (Vitamin K)	Solution for injection 10mg/ml, (1ml)	II - IV	V
10.3	Haematinics			
10.3.1	Ferrous sulphate	Tablets 50mg, 200mg	HC, I - IV	V
10.3.2	Folic acid	Tablets 5mg, 400mcg	HC, I - IV	V
10.3.3	Hydroxocobalamin (Vitamin B12)	Solution for injection 1mg/ml, 1ml	II - IV	E
10.3.4	Iron dextran	Solution for injection 50mg iron in 2ml ampoule	II - IV	E

	Medicine	Presentation	Level	VEN
11	Nutrition			
11.1	Vitamins, minerals and dietary supplements			
11.1.1	Ascorbic acid (vitamin C)	Tablets 50mg, 200mg	I - IV	E
11.1.2	Calcium gluconate	Solution for injection 10%, (5ml,10ml)	III - IV	E
11.1.3	Ergocalciferol (Vitamin D)	Tablets 50,000 IU, solution 3000 IU/ml	II - IV	E
11.1.4	Nicotinamide	Tablets 50mg	II - IV	E
11.1.5	Pyridoxine (Vitamin B6)	Tablets 50mg	I - IV	E
11.1.6	Retinol (Vitamin A)	Capsules/ Tablets 200,000IU	I - IV	E
11.1.7	Riboflavin (Vitamin B2)	Tablets 5mg	III - IV	E
11.1.8	Thiamine (Vitamin B1)	Tablets 50mg, Solution for injection 100mg/5ml	III - IV	E
11.2	Electrolyte and water replacement			
11.2.1	Orally administered			
11.2.1.1	Oral rehydration salts	Powder sachets 27.9g to make 1 litre	I - IV	V
11.2.1.2	Potassium chloride	Tablets slow-release 600mg	II - IV	E
11.2.2	Infusions			
11.2.2.1	Dextrose (glucose)	Solution 5%, 20, 50%	I - IV	V
11.2.2.2	Potassium chloride	Solution 11.2%	II - IV	E
11.2.2.3	Sodium bicarbonate	Solution 4.2%	III - IV	V
11.2.2.4	Sodium chloride (normal saline)	Solution 0.9%	I - IV	V
11.2.2.5	Sodium lactate and glucose (Darrow's)	Solution, full and half strength	I - IV	V

	Medicine	Presentation	Level	VEN
11.2.2.6	Sodium lactate compound (Ringers lactate)	Solution	I - IV	V
11.2.2.7	Water for injection	Solution 2ml, 5ml, 10ml	I - IV	V
11.2.3	Plasma substitutes			
11.2.3.1	Dextran 40, 70	Solution for injection 10%, 6%	III - IV	V
11.2.3.2	Gelatin (as polygeline)	Solution for injection 3.5	III - IV	E
12	Medicines acting on the skin			
12.1	Topical corticosteroids			
12.1.1	Betamethasone	Cream/ Ointment 0.1%	III - IV	E
12.1.2	Hydrocortisone	Cream/ Ointment 1%	I - IV	E
12.2	Soothing preparations			
12.2.2	Calamine	Lotion	I - IV	E
12.3	Topical antifungal preparations			
12.3.1	Miconazole nitrate	Cream 2%	III - IV	E
12.3.2	Ketoconazole	Cream	I - IV	E
12.3.3	Griseofulvin	Tablets 250mg, 500mg	II - IV	E

	Medicine	Presentation	Level	VEN
12.4	Topical anti-bacterial preparations			
12.4.1	Mupirocin	Cream, Ointment 2%	I - IV	E
12.4.2	Silver sulfadiazine	Cream 1%	I - IV	E
12.5	Antiseptic preparations			
12.5.1	Potassium permanganate	Topical solution 1:10,000	I - IV	E
12.6	Topical anti-parasitic preparations			
12.6.1	Benzyl benzoate	Lotion 25%	I - IV	E
12.6.2	Malathion	Lotion 0.5%	I - IV	E
12.6.3	Permethrin	Cream 1%	I - IV	E
12.7	Keratoplastics and keratolytics			
12.7.1	Coal tar	Solution 5%	I - IV	E
12.7.2	Dithranol	Ointment 1%	III - IV	E
12.7.3	Podophylline	Paint 15% in compound benzoin tincture	II - IV	E
12.7.4	Salicylic acid	Ointment 5%, 10%, 20%	I - IV	E
12.8	Acne preparations			
12.8.1	Salicylic acid	Lotion	I - IV	E
12.8.2	Benzyl peroxide	Lotion	I - IV	E

	Medicine	Presentation	Level	VEN
12.9	Surgical disinfectants			
12.9.1	Sodium hypochlorite	Solution 0.1% available chlorine	I - IV	V
12.9.2	Chloroxylenol	Concentrated solution 4.8%	I - IV	E
12.10	Antiseptics			
12.10.1	Cetrimide	Solution 1%	I - IV	E
12.10.3	Chlorhexidine gluconate	Concentrated solution 5%	I - IV	E
12.10.2	Chlorhexidine + Cetrimide	Concentrated solution (1.5%/ 15%)	I - IV	E
12.10.4	Povidone iodine	Solution 10%	I - IV	V
12.11	Topical antivirals			
12.11.1	Acyclovir	Cream 5%, Tablets 200mg	II - IV	E
13	Medicines used in the treatment of diseases of the ear, nose and throat			
13.1	Medicines acting on the ear			
13.1.1	Betamethasone	Ear drops	III - IV	E
13.1.2	Gentamicin + Hydrocortisone	Ear drops	II - IV	E

	Medicine	Presentation	Level	VEN
13.1.3	Sodium bicarbonate	Ear drops	III - IV	E
13.1.4	Olive oil (Vegetable oil)	Ear drops	I - IV	E
13.1.5	Acetic acid	Solution 2%	I - IV	E
13.2	Medicines acting on the nose: topical nasal decongestants			
13.2.1	Saline	Nasal drops	II - IV	E
13.2.2	Xylometazoline	Nasal drops 0.25%, 0.05%	I - IV	E
13.3	Medicines acting on the throat			
13.3.1	Chlorhexidine	Mouth wash 0.2%	I - IV	E
13.3.2	Miconazole	Oral gel	I - IV	E
13.3.3	Nystatin	Oral suspension	I - IV	E
14	Medicines used for the treatment of musculoskeletal disorders			
14.1	Medicines used for rheumatic diseases			
14.1.1	Acetyl salicylic acid	Tablets 300mg	I - IV	V
14.1.2	Ibuprofen	Tablets 200mg	I - IV	E
14.1.3	Hydroxychloroquine	Tablets 200mg	III - IV	E

	Medicine	Presentation	Level	VEN
14.2	Medicines used for gout			
14.2.1	Allopurinol	Tablets 100mg	III - IV	E
14.2.2.	Colchicine	Tablets 500mcg	IV	E
15	Immunological products			
15.1	Antisera, immunoglobulins and anti-toxins			
15.1.1	Anti-D immunoglobulin	Injection	II - IV	V
15.1.2	Diphtheria antitoxin	Injection	II - IV	V
15.1.3.	Mamba anti-sera	Injection	HC, I - IV	V
15.1.4	Polyvalent snake anti-sera	Injection	II - IV	V
15.1.5	Tetanus antitoxin	Injection	I - IV	V
15.2	Vaccines			
15.2.1	Bacillus Calmette-Guerin (BCG)	Injection	I - IV	V
15.2.3	Diphtheria-pertussis	Injection	I - IV	V
15.2.4	Tetanus	Injection	I - IV	V
15.2.5	Haemophilus influenza B	Injection	I - IV	V
15.2.6	Hepatitis B (Pentavalent)	Injection	I - IV	V
15.2.7	Measles + Rubella	Injection	I - IV	V
15.2.8	Poliomyelitis	Injection	I - IV	V
15.2.9	Rabies	Injection	I - IV	V

	Medicine	Presentation	Level	VEN
15.2.8	Tetanus toxoid (TT)	Injection	I - IV	V
15.2.9	Typhoid	Injection	III - IV	E
15.2.10	Yellow fever	Injection	III - IV	E
15.2.11	Human Papilloma Virus (HPV)	Injection	III - IV	E
15.2.12	Rota Virus	Injection	III - IV	E
15.2.13	Pneumococcal Conjugate Vaccine 13	Injection	III - IV	E
15.2.14	Cholera	Injection	III - IV	E
16	Antidotes and other substances used in poisoning			
16.1	General treatment of poisoning			
16.1.1	Activated charcoal	Powder	I - IV	V
16.1.2	Ipecacuanha	Syrup 0.14% ipecacuanha alkaloids	I - IV	V
16.2	Specific treatment of poisoning			
16.2.1	Atropine	Injection 1mg/ml, (1ml)	III - IV	V
16.2.2	Naloxone	Injection 400mcg/ml	III - IV	V
16.2.3	Pralidoxine mesylate	Injection 200mg/ml, (5ml)	III - IV	V
16.2.4	Glycopyrronium bromide	Injection 500mcg/ml	III - IV	V
16.2.5	N-acetylcysteine	Solution 20%	IV	E
16.2.6	Protamine sulphate	Injection 10mg/ml	IV	E

APPENDICES

**FORM FOR PROPOSING REVISIONS IN ZAMBIA ESSENTIAL MEDICINES LIST FORMULARY
ADDITION/DELETION/ CHANGE OF PRESENTATION SPECIAL AUTHORISATION FORM**

Section A To be completed by reporting facility) / proposer	Name of medication to be added / deleted / change of presentation or other (generic / brand): _____	Pertinent Pharmacological Data On Medication _____ Therapeutic Action and Indication for Use: _____ _____ _____ _____
	Desired Dosage: (Tick) ___ Tablet ___ Capsule ___ Injection	
	Other (specify) _____	
	Estimated usage: (Tick) ___ Routine ___ Emergency ___ Clinical Evaluation	
	Is similar- acting medication stocked now in the pharmacy? ___ Yes ___ No	
Reason for addition / deletion /change of presentation or other If addition, please explain the advantage of this medication: _____ _____ _____ _____ _____	Side effects, toxicity, and Precautions: Side effects: Relative contraindications: Caution: Dosages: (Maximum and Minimum)	
Name of proposer: _____		
Signature: _____		
Date: _____		
References: 1) 2)		

SECTION B To be completed by Formulary Committee	FORMULARY COMMITTEE EVALUATION Cost of requested medication _____ Cost of similar –acting item stocked _____ Manufacturer/Registration status _____ Remarks (Advantages, Disadvantages): Chairman of Formulary Committee _____ Date _____	
SECTION C To be completed by the formulary committee	FORMULARY COMMITTEE REPORT Determination: ____ Rejected ____ Approved: Level of use: ____ (e.g. For specialists use) Reasons: Formulary committee chairperson _____ Date _____	

